Ascendis Pharma A/S (ASND)
210.16
+8.92
(+4.43%)
USD |
NASDAQ |
Dec 11, 16:00
211.00
+0.84
(+0.40%)
After-Hours: 07:25
Ascendis Pharma Cash from Investing (Quarterly): -0.2594M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Evaxion AS | -- |
| Novo Nordisk A/S | -2.440B |
| DBV Technologies SA | -0.2404M |
| Cellectis SA | -3.266M |
| Biodexa Pharmaceuticals Plc | -- |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 1.568M |
| Cash from Financing (Quarterly) | 43.34M |
| Free Cash Flow | -123.89M |
| Free Cash Flow Per Share (Quarterly) | 0.0215 |
| Free Cash Flow to Equity (Quarterly) | -24.41M |
| Free Cash Flow to Firm (Quarterly) | 85.16M |
| Free Cash Flow Yield | -0.98% |